Development Strategies Sample Clauses

Development Strategies. CHAPTER 1 provide a coherent enabling framework of support to the ACP’s own development strategies, ensuring complementarity and interaction between the various elements. In this context General framework and within the framework of development policies and reforms pursued by the ACP States, ACP-EC cooperation strategies shall aim at:
Sample 1Sample 2
AutoNDA by SimpleDocs
Development Strategies. Outline key areas requiring further development and strategies to assist the Occasional Teacher to succeed. Occasional Teacher’s Comments: Overall Rating of Occasional Teacher’s Performance:  Satisfactory  Needs Development Administrator Date Occasional Teacher Date Distribution Once document signed by Principal and Occasional Teacher, Principal to provide copy to Occasional Teacher and Human Resources
Sample 1
Development Strategies. At the request of either Party, the Parties shall consult to consider strategies and policies for developing and promoting new economic activities in a Party’s territory that would contribute to realizing the objectives of this Agreement.
Sample 1
Development Strategies. 10.1 The Buyer shall:
Sample 1
Development Strategies. Outline key areas requiring further development and strategies to assist the Occasional Teacher to succeed. Overall Rating of Occasional Teacher’s Performance: ❒ Satisfactory ❒ Needs Development Administrator Date This document constitutes the entire agreement between the Federation and the Board and each of the parties intends to rely on their strict legal rights as set out herein. No representations, verbal or otherwise, are intended to be relied on other than those set out in this written agreement. In witness whereof, the Elementary Teachers’ Federation of Ontario, Occasional Teachers’ Local have executed this Collective Agreement attested by authorized representative of the Elementary Teachers Federation of Ontario representing Elementary Occasional Teachers employed by the Limestone District School Board. Occasional Teacher Date
Sample 1
Development Strategies. The PRIME will develop strategies to complement and execute the systems life cycle processes and practices currently under development by the IRS and ISC. The PRIME and its team will consider multiple development strategies when developing business solutions. These strategies will evaluate: ♦ Import “Drop-In” Solutions – this strategy consists of importing a complete set of business and technical solutions from a successful application in the public or private sector ♦ COTS Package Solutions – this strategy streamlines the package selection process by making use of industry experts and a lab approach to test and apply the package solution ♦ COTS Component Solutions – this strategy integrates individual off-the-shelf components into an overall framework ♦ Reengineered Legacy Asset – this strategy re-uses legacy system components that have been reengineered for modernized systems, such as wrapping existing algorithms in a graphical user interface (GUI) front end ♦ Custom Development – this strategy combines detailed business process designs with the development of applications and data to support those business processes
Sample 1
Development Strategies. The first party could change the second party’s position according to demand or check results of the second party’s performance under the basis of the laws or upon consultation with the second party, made in the principles of reasonableness and honesty.
Sample 1
AutoNDA by SimpleDocs

Related to Development Strategies

  • Product Development Attach all requested documentation and attach additional pages as necessary. For all requirements include efforts of all Sublicensees. If not applicable, please so indicate by N/A.

  • Development 3.3 Within twenty (20) Working Days after the Commencement Date and in accordance with paragraphs 3.10 to 3.12 (Amendment and Revision), the Contractor will prepare and deliver to the Authority for approval the full and final Security Plan which will be based on the draft Security Plan set out in Appendix B.

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Clinical Development Licensee will have sole responsibility for and sole decision making over the clinical development of any Product arising from the Research Program in the Field. Notwithstanding the foregoing, if Licensee wishes to conduct clinical development of a Development Candidate at Penn and Penn has the clinical expertise, interest and ability to run such a trial as assessed at Penn’s sole discretion, such a study will be conducted under a separate Clinical Trial Agreement to be negotiated by the Parties prior to initiation of such study. Such separate clinical trial agreement will include a detailed clinical development plan, including costs and time lines for conducting the Clinical Trial.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Joint Development If joint development is involved, the Recipient agrees to follow the latest edition of FTA Circular 7050.1, “Federal Transit Administration Guidance on Joint Development.”

  • Commercialization Plans As soon as practicable after formation of the JCC (following Acucela’s exercise of an Opt-In Right under Section 3.1), the JCC shall prepare and approve the initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation (and, if applicable, any New Formulation or Other Indication Product) in the Territory. The Parties shall use Commercially Reasonable Efforts to ensure that such initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation is consistent with the general Commercialization Plan outline set forth in Exhibit C attached hereto and incorporated herein (the “General Commercialization Plan Outline”). The JCC shall prepare and approve a separate Commercialization Plan for Commercialization of Licensed Product for the Initial Indication in the Initial Formulation in the Territory and for Commercialization of each Other Indication Product and New Formulation (if any) in the Territory, and shall update and amend each Commercialization Plan not less than annually or more frequently as needed to take into account changed circumstances or completion, commencement or cessation of Commercialization activities not contemplated by the then-current Commercialization Plan. Amendments and revisions to the Commercialization Plan shall be reviewed and discussed, in advance, by the JCC, and Otsuka agrees to consider proposals and suggestions made by Acucela regarding amendments and revisions to the Commercialization Plan. Any amendment or revision to the Commercialization Plan that provides for an increase or decrease in the number of FTEs for any Phase 3b Clinical Trials or Post-Approval Studies as compared to the previous version of the Commercialization Plan, or that provides for addition or discontinuation of tasks or activities as compared to the previous version of the Commercialization Plan, or that moves forward the timetable for activities reflected in the Commercialization Plan, shall provide for a reasonable ramp-up or wind-down period, as applicable, to accommodate a smooth and orderly transition of Commercialization activities to the amended or revised Commercialization Plan. Each Commercialization Plan shall identify the goals of Commercialization contemplated thereunder and shall address Commercialization (including Co-Promotion) activities related to the Licensed Product (including, if applicable, any Other Indication Product), including:

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

  • Initial Development Plan Not later than the Effective Date, Licensee shall have provided Merck with an initial Development plan for the Licensed Product in the Field in the Territory, which shall be incorporated as part of this Agreement as Attachment 3.02(a) (as may be amended in accordance with this Agreement, the “Development Plan”). **CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

Time is Money Join Law Insider Premium to draft better contracts faster.